Can we cure 50% of all multiple myeloma patients in the next five years?
Denosumab: the next big drug in myeloma?
The important issues to consider when deciding when a multiple myeloma patient must start treatment
The future of lymphoma treatment – combining new therapies with molecular diagnosis
Paradigm-changing CAR T-cell therapy for multiple myeloma